What is the 13F Pro Quality Score for REVB?

13F Pro ranks REVELATION BIOSCIENCES, INC. (REVB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View REVB's current score at https://13fpro.ai/research/REVB (free sign-up required for the full ranking).

Which hedge funds own the most REVB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of REVB include ARMISTICE CAPITAL,, SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/REVB as soon as new 13F filings post.

Where does 13F Pro source REVB data?

All REVELATION BIOSCIENCES, INC. fundamentals and ownership data come directly from SEC EDGAR. REVELATION BIOSCIENCES, INC. files with the SEC under CIK 1810560. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is REVB in?

REVELATION BIOSCIENCES, INC. (REVB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is REVB research updated on 13F Pro?

REVB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

REVELATION BIOSCIENCES, INC.(REVB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1810560 REVB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

REVB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for REVELATION BIOSCIENCES, INC. (REVB), a Healthcare sector company. REVB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), REVELATION BIOSCIENCES, INC. reports net income of $-3.0M, free cash flow of $-3.3M. Top institutional holders of REVB by reported 13-F value include ARMISTICE CAPITAL,, SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. REVB trades on the Nasdaq exchange and files with the SEC under CIK 1810560. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REVELATION BIOSCIENCES, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-3.0M

Free Cash Flow

Q1 2026

$-3.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+98.9% YoY

$-120.3KFY 2023

FY19 $-3.6KFY21 $-12.0MFY22 $-10.8MFY23 $-120.3K

Operating Income

+20.3% YoY

$-8.7MFY 2023

FY19 —FY21 $-12.0MFY22 $-10.9MFY23 $-8.7M

EPS (Diluted)

-245.3% YoY

$-0.09FY 2023

FY19 —FY21 $-0.01FY22 $-0.02FY23 $-0.09

Total Assets

+121.9% YoY

$12.2MFY 2023

FY19 $22.7KFY21 $2.0MFY22 $5.5MFY23 $12.2M

Op. Cash Flow

+35.1% YoY

$-7.3MFY 2023

FY19 —FY21 $-11.1MFY22 $-11.2MFY23 $-7.3M

Metric	FY 2023	FY 2022	FY 2021	FY 2019
Net Income	$-120.3K +98.9%	$-10.8M +9.7%	$-12.0M -329389.7%	$-3.6K
Operating Income	$-8.7M +20.3%	$-10.9M +9.1%	$-12.0M	—
EPS (Diluted)	$-0.09 -245.3%	$-0.02 -252.9%	$-0.01	—
Total Assets	$12.2M +121.9%	$5.5M +169.5%	$2.0M +8908.0%	$22.7K
Operating Cash Flow	$-7.3M +35.1%	$-11.2M -1.2%	$-11.1M	—

AI Insight: REVB Financial Trends

REVB remains pre-revenue with persistent $2–3M quarterly operating losses, though equity nearly tripled to $13M in Q1 2026, signaling recent capital raises.

• No revenue recorded across all eight quarters from Q2 2024 through Q1 2026 — company remains fully pre-commercial.

• Operating losses held relatively stable at $2M per quarter from Q3 2024 through Q2 2025, ticking up to $3M in Q4 2025 and Q1 2026.

• Equity expanded sharply from $4M in Q2 2025 to $13M in Q1 2026, suggesting meaningful equity issuance over that period.

⚠ Operating cash burn re-accelerated to $3M in Q1 2026 after stabilizing at $2M — monitor whether burn rate continues climbing.

⚠ Equity of $13M against ongoing $2–3M quarterly burn implies roughly 4–6 quarters of runway without additional financing.

⚠ Any catalysts converting pipeline to revenue would be a critical inflection; none visible in current data.

AI Insight: REVB Ratio Trends

REVB's return metrics remain deeply negative across all periods, with ROE and ROIC showing no path to profitability in available data.

• ROE deteriorated sharply from -69.3% in Q3 2025 to -113.3% in Q4 2025, before partially recovering to -92.7% in Q1 2026.

• ROA swung from -59.3% in Q3 2025 to -86.7% in Q4 2025, then improved slightly to -80.0% in Q1 2026.

• ROIC was -70.6% in Q3 2025 and worsened to -95.2% in Q1 2026, indicating sustained capital destruction.

⚠ OpMargin, NPM, and D/E are unavailable throughout — severe data gaps limit visibility into operating performance and leverage.

⚠ TTM ROE of -76.0% and ROIC of -77.5% confirm persistent losses; any improvement in quarterly NI is a key inflection to monitor.

Get alerted when REVB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for REVELATION BIOSCIENCES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of REVB

ARMISTICE CAPITAL, LLC
$387.9K323,241 sh
SABBY MANAGEMENT, LLC
$119.3K99,432 sh
GEODE CAPITAL MANAGEMENT, LLC
$51.8K43,195 sh
VANGUARD FIDUCIARY TRUST CO
$15.8K13,127 sh
XTX Topco Ltd
$13.7K11,385 sh
UBS Group AG
$4.9K4,115 sh
Tower Research Capital LLC (TRC)
$4.9K4,074 sh
ROYAL BANK OF CANADA
$1.0K747 sh
SBI Securities Co., Ltd.
$413.00344 sh
HARBOUR INVESTMENTS, INC.
$49.0041 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$387.9K	323,241
SABBY MANAGEMENT, LLC	$119.3K	99,432
GEODE CAPITAL MANAGEMENT, LLC	$51.8K	43,195
VANGUARD FIDUCIARY TRUST CO	$15.8K	13,127
XTX Topco Ltd	$13.7K	11,385
UBS Group AG	$4.9K	4,115
Tower Research Capital LLC (TRC)	$4.9K	4,074
ROYAL BANK OF CANADA	$1.0K	747
SBI Securities Co., Ltd.	$413.00	344
HARBOUR INVESTMENTS, INC.	$49.00	41

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put REVB on your watchlist

Track score changes the day REVELATION BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is REVB a good stock to buy?

13F Pro's AI-powered analysis of REVELATION BIOSCIENCES, INC. (REVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REVB are available on the REVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own REVB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REVELATION BIOSCIENCES, INC.'s investment landscape.